Which patients need aggressive lipid-altering therapy?
Hunninghake
D B
DB
Heart Disease Prevention Clinic, University of Minnesota, Minneapolis.
D008076:Cholesterol, HDL / Q000187:drug effects* / Q000378:metabolism; D008078:Cholesterol, LDL / Q000187:drug effects* / Q000378:metabolism; D003327:Coronary Disease / Q000178:diet therapy / Q000188:drug therapy* / Q000378:metabolism; D004359:Drug Therapy, Combination; D015248:Gemfibrozil / Q000627:therapeutic use; D006801:Humans; D006903:Hydroxymethylglutaryl CoA Reductases / Q000627:therapeutic use; D009525:Niacin / Q000627:therapeutic use; D012307:Risk Factors; D014280:Triglycerides / Q000378:metabolism
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D014280:Triglycerides; D009525:Niacin; D006903:Hydroxymethylglutaryl CoA Reductases; D015248:Gemfibrozil